Neuberger Berman Group
IMRX icon

Neuberger Berman Group’s Immuneering IMRX Stock Holding History

Neuberger Berman Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$315K Buy
+76,841
New +$363K ﹤0.01% 1957

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Neuberger Berman Group's IMRX Position: Q3 2026 in Review

Neuberger Berman Group opened a new position in Immuneering (IMRX) in Q3 2026: 76,841 shares worth $315K. The stake represents ﹤0.01% of the portfolio and ranks #1957 among its holdings.

96 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Neuberger Berman Group held 76,841 shares of Immuneering worth $315K as of Q3 2026.
  • Immuneering was a new Neuberger Berman Group position in Q3 2026.
  • Immuneering made up ﹤0.01% of Neuberger Berman Group's portfolio in Q3 2026, its #1957 holding.
  • 96 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Neuberger Berman Group's 13F filing for Q3 2026, filed 13 Nov 2026.